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Benznidazole (Bzn) from the nitroimidazole family and nifurtimox from nitrofurans family,
are drugs used as first and second line treatment for acute and chronic phases of
Chagas disease (CD). Even though skin reactions are frequent, confirmed allergy to
Bzn is rare, and there are few cases reported in the literature. Since CD treatment is
very restrained, the possibility of cross-reactivity between members of the same and
other pharmacological families highlights the importance of an adequate diagnosis that
allows alternative treatments in CD and other diseases. We report a series of 31 patients
(69% women) referred to our Allergy unit with suspected hypersensitivity to Bzn, twenty
three of them with mild reactions and eight of them with severe reactions. LTT with Bzn
was performed in 31 patients and in 8 negative controls. LTT was also performed in 25
and 20 of these patients with nifurtimox and Mtn, respectively. Twenty-one out of thirty-
one patients were Bzn prick tested, and all were negative. We obtained 2/19 positive
results on patch tests to Bzn. LTT with Bzn was positive in 22/31 patients (Sensitivity
75.9% and specificity 100%). The test was considered positive with a stimulation index
≥2. There was a positive result in 7/25 patients for nifurtimox and in 7/20 patients with
Mtn. After negative LTT and skin tests, oral provocation was performed in 4/9 patients,
all negative. LTT is a safe test that seems to be more useful than skin tests (prick and
patch test), particularly in severe reactions, in confirming delayed hypersensitivity to Bzn
and detecting cross reactivity with other imidazoles such as Mtn and reactivity to other
drugs like nifurtimox. Tests for these drugs need to be included in the workup of patients
with hypersensitivity to Bzn in case they are needed as an alternative treatment for CD
or to treat other frequent infectious diseases.
Keywords: benznidazole allergy, lymphocyte transformation test, drug allergy, delayed hypersensitivity,
benznidazole, benznidazole sensitivity
INTRODUCTION
Benznidazole (Bzn) from the nitroimidazole family and nifurtimox from nitrofurans family, are
drugs used as first and second line treatment for acute and chronic phases of Chagas disease
(CD) (Noguerado-Mellado et al., 2017). This treatment has not been modified for more than
100 years after the discovery of the disease because to date, there are no other drugs as effective
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(Pérez-Molina et al., 2013). Metronidazol (Mtn) also belongs
to the nitroimidazole family. It is not used to treat CD, but to
treat other infectious diseases caused by parasites and anaerobic
bacteria (Noguerado-Mellado et al., 2017).
Even though skin reactions are frequent (Carrilero et al.,
2011), confirmed allergy to Bzn is rare and there are few cases
reported in the literature (Álava-Cruz et al., 2014; González-
Ramos et al., 2016; Noguerado-Mellado et al., 2017; Moreno-
Escobosa and Cruz- Granados, 2018). Since CD treatment is very
restrained, the possibility of cross-reactivity between members
of the same and other pharmacological families highlights the
importance of an adequate diagnosis that allows for alternative
treatments in CD and other diseases.
The lymphocyte transformation test (LTT) relies on the ability
of drug-specific memory T cells to proliferate once they have
been stimulated by an antigen (Cabañas et al., 2018). Like other
in vitro tests, it is safer than in vivo tests available (Lochmatter
et al., 2009). To the best of our knowledge, this is the biggest
series reported to this date of hypersensitivity reactions to Bzn,
including both mild and severe clinical manifestations. It is also
the first one in which an in vitro diagnostic test was used, such as
LTT. Thus far, there was only record of cross-reactivity between
Bzn and metronidazole (Prieto et al., 2005; Pérez-Molina et al.,
2013; Noguerado-Mellado et al., 2017).
MATERIALS AND METHODS
We report a series of 31 patients (69% women) referred to
our Allergy unit with suspected hypersensitivity to Bzn, twenty-
three of them with mild reactions such as exanthema/urticaria
and angioedema and eight of them with severe reactions
like drug reaction with eosinophilia and systemic symptoms
(DRESS), Stevens Johnson syndrome (SJS)/ toxic epidermal
necrolysis (TEN), or acute generalized exanthematous pustulosis
(AGEP), (Table 1). None of the patients had any history
of reaction to other drugs. All the patients included in the
sample were originally from Bolivia and El Salvador, but
currently living in Madrid, Spain. LTT with Bzn was performed
in 31 patients and in 8 controls. LTT was also performed
in 25 and 20 of these patients with nifurtimox and Mtn,
respectively. LTT methodology is detailed elsewhere (Pichler
and Tilch, 2004). Briefly, mononuclear cells from peripheral
blood were stimulated with increasing concentrations of Bzn
over 6 days in the presence of 5% autologous serum, and
the proliferation was evaluated through the incorporation
of 3H-thyminide to DNA. Positive control cultures were
performed in the presence of phytohaemagglutinin (Sigma).
The stimulation index (SI) was calculated as the ratio of
3H incorporated by drug-stimulated cultures and basal 3H
incorporation by unstimulated cells (Cabañas et al., 2018). As
the standard criteria, SI ≥ 2 in at least one concentration
was considered positive. LTT was performed after recovery
at least 1 month after steroid treatment was stopped. Bzn
and nifurtimox were purchased from Sigma-Aldrich and stock
solutions were prepared in DMSO. Dilutions were freshly
prepared in RPMI cell culture medium just before use. For
TABLE 1 | Diagnosis and latency time.
Patients Latency time (days) Diagnosis
1 61 urticaria
2 60 macular exantema
3 10 exantema










4 10 papular exantema
5 2 exantema, facial angioedema
















DRESS, drug reaction with eosinophilia and systemic symptoms; SJS, Steven
Johnsons syndrome; AGEP, acute generalized exanthematous pustulosis, TEN,
toxic epidermal necrolysis.
Mtn testing, crushed pills were dissolved in RPMI cell culture
medium. The resulting solution was centrifuged and sterile
filtered before use.
RESULTS
The mean age of the sample was 41 year (SD ± 9) for mild
reactions and 38 year (SD± 9) for severe reactions. Every patient
received treatment with 250–300 mg of Bzn per day. The latency
time between the beginning of treatment and the appearance
of symptoms ranged from 2 to 61 days (mean = 21.3) for mild
reactions and between 1 and 25 days (mean = 13) for severe
reactions (p< 0.05) (Table 1).
Twenty one out of thirty-one patients were Bzn prick tested,
and all were negative. We obtained 2/19 positive results on patch
tests to Bzn. LTT with Bzn was performed in 31 patients with
non-immediate reactions to Bzn, including those with severe
reactions (22/31 positive). The test was considered positive with
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TABLE 2 | Allergy workup.
Prick-test Patch test LTT
Patients BZN Nifurtimox BZN Nifurtimox BZN Nifurtimox MTN ASPS
1 – NP – NP + + – 7
2 – NP – – + + + 7
3 – – – – + – – 7
4 NP NP – NP + + + 7
5 – NP – NP – – – 7
6 – NP NP NP + + + 6
7 – NP – NP – – NP 10
8 – NP NP NP + + – 7
9 – NP NP NP + – – 7
10 – NP – – + – + 6
11 – - – – + – + 7
12 – NP – NP + – NP 7
13 – NP NP NP + – NP 6
14 NP NP – NP + – – 6
15 – NP – NP – – – 6
16 – NP – NP – – – 3
17 - NP + NP – NP NP 11
18 NP NP – NP – NP NP 6
19 – NP – NP – – NP 6
20 – NP – NP + + + 6
21 – – – – – – – 7
22 NP NP NP NP – – – 7
23 – – – + – – 7
24 – NP NP NP + – – 7
25 NP NP NP NP + NP NP 7
26 NP NP NP NP + NP NP 7
27 NP NP NP NP + NP NP 7
28 NP NP NP NP + – – 7
29 NP – NP NP + – NP 7
30 – – + – + + + 7
31 NP NP NP NP + NP NP 9
ASPS, Algorithm of the Spanish Pharmacovigilance System for drug causality assessment; Bzn, benznidazole; Mtn, metronidazole; LTT, lymphocyte transformation test;
NP, not performed.
a stimulation index ≥2. There was a positive result in 7/25
patients for nifurtimox and in 7/20 patients with Mtn. Five of
them were both reactive to nifurtimox and Mtn in addition to
Bzn. After negative LTT and skin tests, oral provocation was
performed in 4/9 patients, and all were negative (Table 2). A total
of eight tolerant patients to Bzn were also studied with LTT assay,
showing specificity of 85.7%.
To assess the sensitivity of LTT with Bzn, we used
the ASPS (Algorithm of the Spanish Pharmacovigilance
System for drug causality assessment) which has been
proven as a suitable approach for evaluation of diagnostic
capacity of LTT (Cabañas et al., 2018). We considered
ASPS ≥ 4 as the standard for a correct diagnosis, finding
an overall sensitivity of 75.9 and 100% specificity. For mild
reactions, a sensitivity of 66.7% and specificity of 100%
was obtained. As for severe reactions, there was a perfect
correlation between LTT and ASPS (sensitivity of 100% and
specificity of 100%).
DISCUSSION
Despite some published data that sustained that patients
with hypersensitivity reactions to Bzn could tolerate
nifurtimox (Pérez-Molina et al., 2013), we found that 33%
of the patients that had positive LTT with Bzn also had a
positive LTT with nifurtimox. This led us to propose that
previous allergy tests should be performed once a patient
develops a hypersensitivity reaction to Bzn before treating
him/her with nifurtimox. Five out of twenty-one patients
(23.8%) were also reactive with both nifurtimox and Mtn
in addition to Bzn. Our results regarding Mtn match the
percentage of cross-reactivity reported in previous series (33.3%)
(Noguerado-Mellado et al., 2017).
Benznidazole and Mtn both belong to nitroimidazole family
and share structural features. However, in patients with positive
LTT to both Bzn and nifurtimox, it is unlikely to be related to
“cross-reactivity” due to lack of structural resemblance. Cases
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with reactivities to drugs without any structural similarity have
been published (Chou et al., 2015).
It has been suggested that cross-reactivity can appear
with memory T cells previously expanded in response to
other pathogens, a phenomenon called heterologous immunity
(White et al., 2015). As the patients had not been previously
exposed to nifurtimox, it is tempting to speculate that this
mechanism could explain our results (and the high frequency
to adverse reactions to Bzn and nifurtimox). Another alternative
mechanism, from a pharmacokinetic point of view, could be
the formation of free radicals or other metabolites that could
promote these types of reactions (Ju and Uetrecht, 2002) but
further studies need to be performed in this regard.
A total of eight tolerant patients to Bzn were also studied
with LTT assay, showing specificity of 85.7%, similarly to
previous results (Nyfeler and Pichler, 1997); nonetheless, a
lower specificity of LTT to nifurtimox (leading to false-positive
results) is possible. Further research is needed to explore the
sensitivity and specificity of LTT to nifurtimox in tolerant but
sensitized donors.
CONCLUSION
In conclusion, LTT is a safe test that seems to be more useful
than skin tests (prick and patch test), particularly in severe
reactions, in confirming delayed hypersensitivity to Bzn and
detecting cross reactivity with other imidazoles such as Mtn
and possibly, reactivity to other drugs like nifurtimox. Tests for
these drugs need to be included in the workup of patients with
hypersensitivity to Bzn, in case they are needed as an alternative
treatment for CD or to treat other frequent infectious diseases.
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